Sodium Hyaluronate

15 ePosters and In-Person Presentations Will Include Clinical Data on Blink™ NutriTears® Supplement for Dry Eyes, Blink® Triple Care Lubricating Eye Drops and MIEBO® (Perfluorohexyloctane Ophthalmic Solution) VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 12 ePosters during the American Optometric Association (AOA) Optometry’s Meeting ePoster Session, taking place virtually May 29-30, 2024. The company will also have three live presentations and host nine education events during the in-person meeting, taking place in Nashville June 19-22, 2024. The OnDemand ePosters will feature new data on the early adoption of MIEBO and real-world patient experiences with Bausch + Lomb INFUSE® Multifocal silicone hydrogel daily disposable contact lenses. An evaluation of the performance of Biotrue® Hydration Plus Multi-Purpose Solution among two different patient demographics – soft contact lens wearers who are also frequent gamers and users planning to stop wearing lenses due to discomfort – will also be highlighted. The live, in-person presentations will include clinical data evaluating Blink NutriTears clinically proven nutritional supplement for dry eyes*, which was selected by AOA as one of the top five Optometry’s Meeting abstracts. Two other presentations will showcase clinical evaluation data for Blink Triple Care Lubricating Eye Drops, the first and only over-the-counter eye drop with both hyaluronate and a nano-emulsion lipid in the unique formula. The complete list of scientific ePosters and live presentations, as well as details for the featured education events, is as follows: e-Poster Presentations “A Multi-country Assessment of Satisfaction with a Spherical Silicone Hydrogel Daily Disposable Contact Lens Among New Contact Lens Wearers and Their Eyecare Professionals.” Reindel et al. “Comparison of Clinical Studies from the US and India of a Multi-Ingredient Oral Supplement.” Gioia et al. “Early Adoption and Utilization of Perfluorohexyloctane for Dry Eye Disease.” Alexander et al. “Evaluation of the Efficacy of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” Evans et al. “Evaluation of the Safety of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” Evans et al. “Frequent Gamers Tag a Novel Contact Lens Solution with High Satisfaction” Shahidi et al. “Improvement in Non-Invasive Tear Break-Up Time after Instillation of One Drop of Brimonidine Tartrate 0.025%.” Moore et al. “Ocular Vasoconstrictors: Does Mechanism of Action Make a Difference?” Moore et al. “On the Verge of Dropout: An In-Home Use Test of a Novel Contact Lens Solution Among Planned Replacement Contact Lens Wearers.” Shahidi et al. “Patient Performance Assessment with Multifocal Toric Silicone Hydrogel Contact Lenses.” Rah et al. “Patient-reported Instillation Comfort and Eyedrop Acceptability of Perfluorohexyloctane Ophthalmic Solution in Pivotal Clinical Studies.” Cunningham et al. “Real-world Evaluation of a Daily Disposable Silicone Hydrogel Multifocal Contact Lens.” Rah et al. Live Presentations “Clinical Evaluation of a Novel Lipid-Containing Eye Drop.” Coats et al. “Clinical Evaluation of a Multi-Ingredient Oral Supplement on Dry Eye Symptoms and Tear Volume.” Gioia et al. “Comparison of a Novel Lipid Nano-Emulsion Eye Drop with an Existing Lubricating Eye Drop.” Coats et al. Featured Education Events Wednesday, June 19 “Showcasing Inflammation and IOP Control with Bausch + Lomb” 6:30 p.m. CDT at The Palm (140 5th Avenue South, Nashville, Tenn.) Nora Lee Cothran, OD, FAAO, and Walter Whitley, OD, FAAO, will discuss the benefits of using LOTEMAX® SM (loteprednol etabonate ophthalmic gel), 0.38%, and VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%. Register in advance. Thursday, June 20 “Showcasing Inflammation and IOP Control with Bausch + Lomb” 8:00-9:00 a.m. CDT at the Music City Center (201 Rep. John Lewis Way S, Nashville, Tenn.; room #104AB) Richard Madonna, OD, and Justin Schweitzer, OD, will discuss the benefits of using LOTEMAX SM (loteprednol etabonate ophthalmic gel), 0.38%, and VYZULTA (latanoprostene bunod ophthalmic solution), 0.024%. “NEW Breakthrough Supplement for Dry Eyes from Bausch + Lomb: Blink NutriTears” 12:00-1:00 p.m. CDT at the Music City Center (201 Rep. John Lewis Way S, Nashville, Tenn.; room #104AB) Selina McGee, OD, FAAO, and Julie Poteet, OD, will lead a conversation on the new Blink NutriTears, a breakthrough, nutritional daily supplement for dry eyes. “Current Thinking in Dry Eye Disease: Contemporary Perspectives on a Complex Condition” 6:30-8:30 p.m. CDT at Morton’s Steakhouse (618 Church Street, Nashville, Tenn.) Learn about MIEBO, the first and only prescription eye drop that directly targets tear evaporation, as well as XIIDRA® (lifitegrast ophthalmic solution), 5%, the only nonsteroid anti-inflammatory prescription eye drop that can start to deliver dry eye symptom relief in just two weeks.1-2 Register in advance. “A NightCap in Nashville with Blink NutriTears” 8:00-10:30 p.m. (presentation at 9:00 p.m. CDT) at The Bell Tower (400th Ave. S, Nashville, Tenn.) Join Cecelia Koetting, OD, FAAO, to lean about Blink NutriTears clinically proven nutritional supplement for dry eyes. Friday, June 21 “Rethinking Dry Eye Disease: A Contemporary Approach to a Complex Condition” 8:00-9:00 a.m. CDT at the Music City Center (201 Rep. John Lewis Way S, Nashville, Tenn.; room #104AB) Cecelia Koetting, OD, FAAO, and Nathan Lighthizer, OD, FAAO, will discuss the benefits of and differences between MIEBO and XIIDRA. “The Science of Eye Beauty with LUMIFY EYE ILLUMINATIONS™” 12:40-1:00 p.m. CDT at the Music City Center (201 Rep. John Lewis Way S, Nashville, Tenn.; Exhibit Hall, Eye Talks Stage) Join Selina McGee, OD, FAAO, to learn about LUMIFY EYE ILLUMINATIONS, a clinically proven specialty eye care line. Saturday, June 22 “A Family of Eye Care Products with Innovations for Every Stage of Life” 9:00-10:00 a.m. CDT at the Music City Center (201 Rep. John Lewis Way S, Nashville, Tenn.; room #104AB) Selina McGee, OD, FAAO, Mitch Ibach, OD, FAAO, and John Womack, OD, will share practical patient cases using products from across the Bausch + Lomb consumer, vision care and pharmaceutical portfolios. “The Puzzle of Dry Eye: Targeted Approaches to a Multifactorial Condition” 12:00-1:00 p.m. CDT at the Music City Center (201 Rep. John Lewis Way S, Nashville, Tenn.; room #104AB) Learn about the complex dry eye puzzle, Blink NutriTears, as well as MIEBO and XIIDRA. AOA’s Celebration of Optometry Event Additionally, Bausch + Lomb is the title sponsor of AOA’s Celebration of Optometry event, taking place at FGL House (120 3rd Ave South, Nashville, Tenn.) at 7 p.m. CDT on Friday, June 21. During the event, attendees will have the opportunity to learn about Bausch + Lomb’s latest innovations, including Bausch + Lomb INFUSE® for Astigmatism and Blink NutriTears. Important Safety Information for MIEBO INDICATION MIEBO (perfluorohexyloctane ophthalmic solution) is used to treat the signs and symptoms of dry eye disease. IMPORTANT SAFETY INFORMATION Patients should remove contact lenses before using MIEBO and wait for at least 30 minutes before reinserting. It is important for patients to use MIEBO exactly as prescribed. It is not known if MIEBO is safe and effective in children under the age of 18. The most common eye side effect seen in studies was blurred vision (1% to 3 % of patients reported blurred vision and eye redness). You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. Click here for full Prescribing Information for MIEBO. WHAT IS XIIDRA? XIIDRA (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease. IMPORTANT SAFETY INFORMATION Do not use XIIDRA if you are allergic to any of its ingredients. Seek medical care immediately if you get any symptoms of an allergic reaction. The most common side effects of XIIDRA include eye irritation, discomfort or blurred vision when the drops are applied to the eyes, and an unusual taste sensation. To help avoid eye injury or contamination of the solution, do not touch the container tip to your eye or any surface. If you wear contact lenses, remove them before using XIIDRA and wait for at least 15 minutes before placing them back in your eyes. It is not known if XIIDRA is safe and effective in children under 17 years of age. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. Click here for full Prescribing Information for XIIDRA. Important Safety Information for LOTEMAX SM INDICATION LOTEMAX SM (loteprednol etabonate ophthalmic gel) 0.38% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. IMPORTANT SAFETY INFORMATION LOTEMAX SM, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If LOTEMAX SM is used for 10 days or longer, IOP should be monitored. Use of corticosteroids may result in posterior subcapsular cataract formation. The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those with diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infections. Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal cultures should be taken when appropriate. Contact lenses should not be worn when the eyes are inflamed. There were no treatment-emergent adverse drug reactions that occurred in more than 1% of subjects in the three times daily group compared to vehicle. Click here for full Prescribing Information for LOTEMAX SM. Important Safety Information for VYZULTA INDICATION VYZULTA (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. IMPORTANT SAFETY INFORMATION Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent. Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation. Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation. Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients. Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration. Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%). Please click here for full Prescribing Information. Patients are encouraged to report negative side effects of these prescription drugs to the FDA. Visit or call 1-800-FDA-1088. About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on X, LinkedIn, Facebook and Instagram. Forward-looking Statements This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. *This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. References XIIDRA significantly reduced symptoms of eye dryness at 2 weeks in two out of four clinical studies. XIIDRA. Prescribing information. Bausch & Lomb Inc; 2023. © 2024 Bausch + Lomb. BLS.0079.USA.24 View source version on businesswire.com: Contacts Investor Contact: George Gadkowski george.gadkowski@bausch.com (877) 354-3705 (toll free) (908) 927-0735 Source: Bausch + Lomb Corporation View this news release online at:

Evolus dermal filler, Evolysse™ Lift, met primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months; Secondary endpoints for improvement in nasolabial fold severity showed statistically significant differences compared to Restylane-L at all measured timepoints for the entire 12-month study period Evolus dermal filler, Evolysse™ Smooth, met primary endpoint of non-inferiority and demonstrated superiority to Restylane-L at 6 months; Secondary endpoints for improvement in nasolabial fold severity showed statistically significant differences compared to Restylane-L at 6 and 9 months The safety profiles were similar between the two Evolysse™ dermal filler products and Restylane-L and there were no treatment-related serious adverse events On track to submit Premarket Approval (PMA) applications for the first two Evolysse™ dermal filler products with the FDA within the next 90 days NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal nasolabial fold (NLF) study of dermal filler products Evolysse™ Lift and Smooth. Data were presented at the 2024 SCALE Meeting on May 17, 2024, in Nashville. “Achieving positive topline results in our NLF study is a pivotal step supporting the upcoming submission of our Premarket Approval application for the U.S. launch of our dermal filler lines. Complementing our flagship neurotoxin Jeuveau® – the fastest growing neurotoxin in the U.S. for the past three years1 – our Evolysse™ line of dermal fillers expands our total addressable market by 78%,” said David Moatazedi, President and Chief Executive Officer. “Built on the earlier success of the European head-to-head trial, the consistency of results from this pivotal trial for Evolysse™ Lift and Smooth were impressive when compared to the previously shared European nasolabial fold data,” said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D. “The R&D team remains on track to complete and submit the PMA to the FDA within the next 90 days and this data increases our confidence in the submission.” “As an investigator in this pivotal trial, I had first-hand experience in treating patients with the new Evolysse™ HA filler line that is manufactured using a novel “Cold Technology” process which is aimed at preserving the natural structure of the HA molecule,” said Dr. Steven Dayan, MD. “Clinically, I found the product to be precise and I could treat patients to optimal correction. I was also struck by the fact that despite using the same amount of product between the treatment and control, there seems to be more of a difference in the correction when looking at the Evolysse™ treatment arm.” Study Design The U.S. NLF pivotal study was a multicenter, blinded, split face, controlled, non-inferiority design. Patients were followed for 12 months from initial treatment. A total of 140 patients were enrolled and divided evenly across two investigational arms. Patients were randomized to receive Evolysse™ Lift or Evolysse™ Smooth in one NLF and Restylane-L in the contralateral NLF. This split face design allowed each individual patient to experience one of the Evolysse™ fillers and the control at the same time. The 6-month primary endpoint measured the change in NLF severity from baseline and was assessed by a blinded independent photographic review panel using a validated 5-point nasolabial scale. Results The Evolysse™ Lift vs Restylane-L arm met the primary endpoint of non-inferiority and demonstrated superiority, with a mean NLF severity score difference of -0.3 (95% CI: -0.500, -0.032, non-inferiority margin 0.5) and corresponding p-value of 0.03. As a secondary endpoint, the mean grade change in the NLF severity, as assessed by the blinded, live evaluator demonstrated a statistically significant difference (p<0.05) at all timepoints from 6 weeks to 12 months between Evolysse™ Lift and the control. The Evolysse™ Smooth vs Restylane-L arm also met the primary endpoint of non-inferiority and demonstrated superiority, with a mean NLF severity score difference of -0.2 (95% CI: -0.416, -0.019, non-inferiority margin 0.5) and corresponding p-value of 0.02. As a secondary endpoint, the mean grade change in the NLF severity, as assessed by the blinded, live evaluator demonstrated a statistically significant difference (p<0.05) at 6 and 9 months between Evolysse™ Smooth and the control. The safety profiles were similar between the two Evolysse™ dermal filler products compared to their respective controls and there were no treatment-related serious adverse events. Evolus remains on track to submit Premarket Approval (PMA) applications for the first two Evolysse™ dermal filler products with the FDA within the next 90 days. The Evolysse™ Lift filler will be positioned as the most versatile and highest use filler in the product line. The Evolysse™ Smooth filler is a softer product than Lift, providing additional versatility. 1 Measured by comparing year-over-year revenue growth of each aesthetic neurotoxin on the market for the entirety of each comparable year. About Evolus, Inc. Evolus (NASDAQ: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme®, a line of unique dermal fillers currently in late-stage development. Visit us at , and follow us on LinkedIn, X, Instagram or Facebook. Forward-Looking Statements This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including statements about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical or current facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, or other comparable terms intended to identify statements about the future. The company’s forward-looking statements include, but are not limited to, statements related to anticipated product launches; market size, conditions and consumer demand; and the timing of regulatory submissions and approvals. The forward-looking statements included herein are based on our current expectations, assumptions, estimates and projections, which we believe to be reasonable, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to, uncertainties associated with our ability to comply with the terms and conditions in the Medytox Settlement Agreements, our ability to fund our future operations or obtain financing to fund our operations, unfavorable global economic conditions and the impact on consumer discretionary spending, uncertainties related to customer and consumer adoption of Jeuveau® and Evolysse™, the efficiency and operability of our digital platform, competition and market dynamics, our ability to successfully launch and commercialize our products in new markets, including the Evolysse™ dermal filler product line in the U.S., our ability to maintain regulatory approvals of Jeuveau® or obtain regulatory approvals for new product candidates or indications, our reliance on Symatese to achieve regulatory approval for the Evolysse™ dermal filler product line in the U.S., and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled “Risk Factors” in our Annual Report on Form 10-K Form and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed with the Securities and Exchange Commission on May 7, 2024. These filings can be accessed online at . Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. If we do update or revise one or more of these statements, investors and others should not conclude that we will make additional updates or corrections. Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd. Estyme® is a trademark of Symatese Aesthetics S.A.S. Restylane® is a trademark of Galderma S.A.